- freely available
Toxins 2013, 5(12), 2403-2419; doi:10.3390/toxins5122403
Published: 4 December 2013
Abstract: In this work, we describe the molecular cloning and pharmacological properties of an acidic phospholipase A2 (PLA2) isolated from Bothrops pauloensis snake venom. This enzyme, denominated BpPLA2-TXI, was purified by four chromatographic steps and represents 2.4% of the total snake venom protein content. BpPLA2-TXI is a monomeric protein with a molecular mass of 13.6 kDa, as demonstrated by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) analysis and its theoretical isoelectric point was 4.98. BpPLA2-TXI was catalytically active and showed some pharmacological effects such as inhibition of platelet aggregation induced by collagen or ADP and also induced edema and myotoxicity. BpPLA2-TXI displayed low cytotoxicity on TG-180 (CCRF S 180 II) and Ovarian Carcinoma (OVCAR-3), whereas no cytotoxicity was found in regard to MEF (Mouse Embryonic Fibroblast) and Sarcoma 180 (TIB-66). The N-terminal sequence of forty-eight amino acid residues was determined by Edman degradation. In addition, the complete primary structure of 122 amino acids was deduced by cDNA from the total RNA of the venom gland using specific primers, and it was significantly similar to other acidic D49 PLA2s. The phylogenetic analyses showed that BpPLA2-TXI forms a group with other acidic D49 PLA2s from the gender Bothrops, which are characterized by a catalytic activity associated with anti-platelet effects.
Bothrops pauloensis is a venomous snake widely distributed throughout the Brazilian territory, except in the Amazonian region of Brazil. This species is particularly common in the Triangulo Mineiro region, in the southwest of Minas Gerais State .
Rodrigues et al.  described the repertoire of venom toxins from B. pauloensis by snake proteomics and venom gland transcriptomic surveys. The main toxins present in B. pauloensis snake venom include metalloproteinases, phospholipases A2, serine proteinases, l-amino acid oxidases, disintegrins, nucleotidases and hyaluronidases, among others . Both approaches indicated metalloproteinases, vasoactive (bradykinin-potentiating) peptides and phospholipases A2 as the major toxin classes.
Phospholipases A2 (PLA2) (E.C. 188.8.131.52) represent a superfamily of lipolytic enzymes that catalyze the hydrolysis of the 2-acyl ester of the phospholipids, releasing free fatty acids and lysophosphatids [3,4]. PLA2s are classified into 15 groups that are further subdivided into several groups (sPLA2—secreted; cPLA2—cytosolic; iPLA2—Ca2+ independent; LpPLA2—lipoprotein-associated), all of which display differences in amino acid sequence, disulfide bonds, tissue specificity and cellular functions [5,6].
PLA2s are present in snake venoms and are characterized by low molecular mass (13–18 kDa), histidine at the catalytic site, Ca2+ bound at the active site, as well as six conserved disulfide bonds with one or two variable disulfide bonds . These PLA2s can be divided into two groups, I and II, whereby the second is subdivided into two classes, and are present in snake venoms from the Viperidae family. These classes are D49 PLA2s, which display an Asp residue at position 49, with high catalytic activity upon artificial substrates; and Lys49 PLA2s, that presents a Lys residue at position 49, with low or no catalytic activity [8,9].
The different PLA2s isoforms that have already been isolated from B. pauloensis snake venom include: BnpTX-I and BpnTX-II (D-49 basic) , BnSP-6 and BnSP-7 (K-49 basic)  and Bp-PLA2 (D-49 acidic) . These toxins present some toxic and/or pharmacological effects characterized as neurotoxicity, myotoxicity, cytotoxicity, inhibition of platelet aggregation, anticoagulation, edema, convulsion and hypotension [3,8,9]. The present study describes the molecular cloning, as well as the enzymatic and pharmacological properties of an acidic phospholipase A2 from B. pauloensis snake venom.
2. Results and Discussion
An acidic PLA2 isolated from the venom of B. pauloensis was obtained by four chromatographic procedures in the present work. The first step consisted of an ion exchange chromatography on CM-Sepharose column and resulted in six major protein peaks (Figure 1A). The fraction named CM-1, with phospholipase A2 activity (Table 1), was further fractionated on Sephacryl-S300 HR HiPrep 26/60 (filtration chromatography) and resulted in seven new protein fractions, denominated S1–S7 (Figure 1B). S4, which displayed high PLA2 activity, was applied on a Hi-Trap Q FF ion-exchange column and resulted in two peaks, Q1 and Q2 (Figure 1C). The Q2 fraction was then applied on a reverse phase high performance liquid chromatography (HPLC) C2–C18 µRPC 4.6/100 (GE HealthCare) and the acidic PLA2, named BpPLA2-TXI, was eluted with approximately 80% of the Solvent B (Figure 1D). BpPLA2-TXI was shown to be homogeneous by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 1E) with an apparent molecular mass of 15,000 Da in the presence of the reducing agent. Analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) (Figure 2) of the intact protein revealed a purified protein with a molecular mass of 13,682 Da. The theoretical pI of BpPLA2-TXI was found to be 4.98, as calculated based on a deduced sequence of cDNA by using the program CLC Sequence Viewer 6 (CLC bio, Aarhus, Denmark; http://www.clcbio.com/index.php?id=28), confirming that BpPLA2-TXI is an acidic PLA2.
|Table 1. Protein yield and recovery of enzymatic activity of the crude venom and fractions.|
|Fraction||Protein *||Phospholipase activity **|
|mg||% Rec||U/mg||U-total||Purification factor|
* Protein concentration was determined by Bradford (1976); ** Phospholipase A2 activity was determined by DE HAAS (1968).
Table 1 shows total protein yield and recovery of PLA2 activity. BpPLA2-TXI exhibited a specific PLA2 activity of 142 U/mg, three-fold higher than the crude venom (51 U/mg). BpPLA2-TXI, an acidic PLA2 isoenzyme isolated from B. pauloensis venom, presented a considerable recovery of the specific phospholipase activity (Table 1). These results are in agreement with previous studies involving PLA2 from snake venoms, in which the catalytic activity of D49 acidic PLA2s are higher than that related to D49 basic PLA2s [8,9,11,12].
The indirect hemolytic activity was performed to assess the stability of BpPLA2-TXI. The protein was stable when submitted to different pH values (3.5, 5.2, 6.0, 7.5, 9.5, 10.5) (Figure 3A) or temperatures (4, 20, 25, 37, 45, 60 and 100 °C) (Figure 3B). However, PLA2 activity was reduced when BpPLA2-TXI was subjected to 100 °C for 30 min, suggesting that denaturation causes loss of protein stability, thereby decreasing its activity. The majority of PLA2s from snake venoms are highly stable due to the presence of intra-chain disulfide bonds present in their structures [8,13].
BpPLA2-TXI inhibited platelet aggregation induced by collagen and ADP in a dose-dependent manner (Figure 4). Acidic PLA2s Asp-49 from several bothropic snake venoms are able to inhibit platelet aggregation induced by physiological agonists such as collagen and ADP [8,14]. The anti-platelet effect induced by PLA2s might be due to direct interference of the catalytic site in this activity or because of the C-terminal region of these proteins . Some studies demonstrated that, when PLA2s are modified by bromophenacyl bromide (p-BPB), the His48 residue present in the active site is alkylated, resulting in a drastic loss or reduction of the enzymatic activity and/or pharmacological effects of PLA2s [8,15,16,17]. BpPLA2-TXI was efficient in inhibiting the platelet aggregation, although further experiments should be conducted to increase the knowledge of the mechanism of action of BpPLA2-TX on platelet aggregation.
BpPLA2-TXI also induced mouse paw edema (Figure 5), which was more extensive 3 h after administration of the toxin. Some D49 acidic phospholipase A2 forms have been characterized and have also shown similar effects [11,12,14]. Several factors may influence edema induction by these toxins that catalyze the breakdown of the phospholipids and release arachidonic acid, a precursor of eicosanoids, which can mediate the inflammatory response and induce edema .
BpPLA2-TXI induced significant increases in the plasma CK (creatine kinase) levels 3h after administration of the toxin in the gastrocnemius muscle. However, this effect was reduced when compared with CK levels induced by BnSP-7, a basic K49 PLA2 (Figure 6). Some D49 PLA2s do not present myotoxicity [12,19,20], but some studies have reported that these toxins may injure muscle fibers to a lesser degree [11,21].
The mechanism by which these toxins induced the myotoxicity is not precisely defined. Some works suggest an independent mechanism from the catalytic site, provoking a disturbance of the sarcolema through the insertion of the toxin in the C-terminal region inside the plasmatic membrane, leading to influx of calcium and consequent muscular necrosis . However, other authors who have accomplished modification in the PLA2 with p-BPB have observed a loss or decrease of myotoxic activity , suggesting that myotoxicity of the acidic D49 PLA2 is directly related to the catalytic site.
The cytotoxicity of the BpPLA2-TXI on some tumor cells was evaluated on MEF (Mouse Embryonic Fibroblast), Sarcoma 180 (TIB-66), TG-180 (CCRF S 180 II) and Ovarian Carcinoma (OVCAR-3). BpPLA2-TXI presented low cytotoxicity against TG-180 (CCRF S 180 II) and Ovarian Carcinoma (OVCAR-3) and did not show such activity against MEF (Mouse Embryonic Fibroblast) and Sarcoma 180 (TIB-66) (data not shown). Several authors have reported that some basic snake venom PLA2s produce high cytotoxic activity against tumor cells [23,24]. Meanwhile, other studies have revealed that the acidic PLA2 present low or no cytotoxicity [8,19].
The sequence of the first 48 amino acid residues from BpPLA2-TXI was determined by Edman degradation (Figure 7) and the complete sequence was deduced further by cDNA. This sequence was recorded in the GenBank under Accession No. JK998826.
The nucleotide sequence of the BpPLA2-TXI showed 417 bp, codifying a mature protein of 122 amino acid residues (Figure 7). These results are in agreement with other works concerning acidic PLA2s, which presents 120–135 amino acid residues and 400–500 bp [9,19,20,25]. Analysis of the PLA2 primary sequence reveals that this enzyme possesses not only an Asp residue in the 49th position (D49) but also many other conserved residues (24YGCYCGWGG32; H48) involved at the Ca2+ binding and catalytic sites.
BpPLA2-TXI was aligned with other PLA2 sequences from B. pauloensis (results not shown). High identity was visualized (about 77%) with Bp-PLA2 , as expected, since both are acidic D49 PLA2s. Multiple alignments of the BpPLA2-TXI sequence with other acidic D49 PLA2s are shown in Figure 8. The best alignment scores pointed by ClustalW were with PLA2 from Bothrops erythromelas and Sistrurus catenatus, representing 99% and 89%, respectively. BpPLA2-TXI possesses many conserved domains that are common to D49 PLA2s, including 14 cystein residues which form seven disulfide bonds, and presents other residues involved with the calcium binding and catalytic sites as well. According to the results published by Rodrigues et al.  and of the present study, we suggest that Bp-PLA2 and BpPLA2-TXI may be isoforms present in B. pauloensis snake venom.
The PLA2 gene is involved in an accelerated evolution by substitutions in protein-encoding regions and appears to be universal for all the PLA2-encoding genes in snake venom glands of the crotaline snakes [26,27,28,29]. As shown in Figure 9, BpPLA2-TXI, together with other acidic PLA2s, formed a separate group from basic PLA2s, suggesting that the replacement of the D49 by the K49 residue is a derived characteristic, although additional studies need to be accomplished in order to elucidate this aspect. Tsai et al. , when isolating and characterizing several PLA2s from Crotalus viridis viridis snake venoms from different regions, showed that these acidic PLA2s were capable of inhibiting platelet aggregation and presented a glutamate (E) residue at Position 6. BpPLA2-TXI also posseses the E6 residue and is able to inhibit platelet aggregation.
3. Experimental Section
3.1. Material and Animals
B. pauloensis dried crude venom was purchased from Serpentarium Bioagents (Batatais, SP, Brazil) and maintained at −20 °C. This serpentarium is registered with the Brazilian Institute of the Environment and Renewable Natural Resources (n 471301). Male Swiss mice (18–25 g) were obtained from and maintained in the Center for Animal Experimentation and Housing (CEBEA) at the Federal University of Uberlândia (UFU), Uberlândia, MG, Brazil. Animal experimentation procedures were approved by the UFU Ethics Committee for Animal Utilization (protocol number 046/09). CK-Nac Kit was purchased from Analisa (Belo Horizonte, Brazil). Adenosine diphosphate (ADP) and Collagen were acquired from Helena Laboratories (Beaumont, TX, USA). CM-Sepharose resin was purchased from Amersham Biotec (São Paulo, Brazil). All other reagents used were of analytical grade.
3.2. Isolation of Acidic Phospholipase A2
The acidic PLA2 was isolated by a combination of an ion exchange chromatography on CM-Sepharose fast flow , a gel filtration Sephacryl S-300  and an ion exchange Capto-Q column (Amersham Biotec, São Paulo, Brazil), according to methods previously standardized by our research group. Initially, a sample containing 170 mg of desiccated B. pauloensis venom was dispersed into 2.0 mL of 0.05 M ammonium bicarbonate (AMBIC, Sigma, St. Louis, MO, USA) buffer, pH 7.8, cleared by centrifugation at 10,000 × g for 10 min at 4 °C and submitted to CM-Sepharose Fast Flow column (2.0 × 20 cm) which was previously equilibrated and initially eluted with the same buffer. A linear gradient was then applied up to 0.05 M Ambic buffer, pH 7.8 and fractions of 1 mL/tube were collected at a flow rate of 6.6 mL/h.
The fraction with PLA2 activity (CM1) was collected and gel filtrated on a Sephacryl S-300 HR HiPrep 26/60 (GE HealthCare, Uppsala, Sweden), equilibrated and eluted with 0.05 M Ambic buffer, pH 7.8. Fractions of 2.0 mL/tube were collected at a flow rate of 12.0 mL/h. The fraction with PLA2 activity (S4) was further submitted to an anionic exchange HiTrap Q FF column (GE HelthCare, Uppsala, Sweden) equilibrated with 0.05 M AMBIC buffer, pH 7.8. A linear gradient was then applied up to 0.5 M AMBIC buffer (AMBIC, Sigma, St. Louis, MO, USA), pH 7.8 and fractions of 1.0 mL/tube were collected at a flow rate of 6.0 mL/h. The active fraction (Q2) was rechromatographed by reverse-phase chromatography on a C2–C18 µRPC 4.6/100 (GE HelthCare, Uppsala, Sweden) column, previously equilibrated with solvent A (0.1% trifluoroacetic acid and 4% acetronitrile). The elution of the protein was conducted using a linear gradient of solvent B (0.1% trifluoroacetic acid and 80% acetronitrile) from 0% to 100%, at a flow rate of 0.5 mL/tube for 33 min. All steps of the purification procedure were carried out at room temperature (25 °C). The acidic PLA2 derived from RP-HPLC, named BpPLA2-TXI, was lyophilized and used for biochemical characterization and pharmacological studies.
3.3. Determination of Mr
Polyacrylamide gel electrophoresis (PAGE), in the presence of sodium dodecyl sulfate (SDS-PAGE), was performed according to Laemmli . Samples were heated at 100 °C for 5 min and run under reducing (10% β-mercaptoethanol) and non-reducing conditions. The gel was stained with Coomassie Brilliant Blue R-250. The Mr was estimated by interpolation from a linear logarithmic plot of relative molecular mass versus migration distance. The molecular mass markers used were: bovine serum albumin (66 kDa), ovalbumin (45 kDa), glyceraldehyde-3-phosphate dehydrogenase (36 kDa), carbonic anhydrase (29 kDa), trypsinogen (24 kDa), trypsin inhibitor (20 kDa) and α-lactalbumin (14.2 kDa) (Amersham Biosciences, São Paulo, Brazil).
3.4. MALDI TOF Mass Spectrometry
BpPLA2-TXI was also submitted to mass spectrometric analysis, using an AutoFlex III MALDI-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) controlled by the software FlexControl 3.0 (Bruker Daltonics, Bremen, Germany). The sample was mixed with sinapinic acid matrix solution (1:1, v/v) directly onto a target plate (Bruker Daltonics, Bremen, Germany) and dried at room temperature. The mean mass of the protein was obtained in linear mode with external calibration, using Protein Calibration Standard (Bruker Daltonics, Bremen, Germany). The software Flex Analysis 3.0 (Bruker Daltonics, Bremen, Germany) was used for analysis of mass spectrometric data.
3.5. Phospholipase A2 Activity
Phospholipase activity of BpPLA2-TXI was determined upon egg-yolk emulsion according to  and by the indirect hemolysis method, using washed mice erythrocytes and hen’s egg-yolk emulsion as substrate as described by .
BpPLA2-TXI stability at various pH intervals (50 mM ammonium formate pH 3.5; 50 mM sodium acetate pH 5.2; pH 6.0; 50 mM Tris HCl pH 7.5, 9.5 and 50 mM sodium borate pH 10.5) and temperatures (4 °C, 20 °C, 25 °C, 37 °C, 45 °C, 60 °C and 100 °C) was carried out as described by . For this assay, 5 µg of BpPLA2-TXI were first incubated for 30 min with 50 μL of different buffer solutions at various pH intervals and temperatures, and the enzymatic assays were subsequently performed as described above .
3.6. Platelet Aggregation
The platelet aggregation was determined by using the method previously described by Fuly et al. , with modifications. Platelet-rich plasma (PRP) was prepared from mouse blood collected in the presence of citrate (0.31% w/v) and centrifuged at 360 × g for 15 min at room temperature. Washed platelets (WP) were prepared by centrifugation of PRP at 1800 × g for 12 min at room temperature. Platelets were resuspended in a Tyrode-BSA buffer and the final pH was adjusted to 7.5. Platelets were counted and their density adjusted to 3–4 × 105 cells/µL. The platelet aggregation was measured turbidimetrically by AggRAM aggregometer (Helena Laboratories, Beaumont, TX, USA). WP suspended in Tyrode-BSA buffer (225 µL) were previously incubated at 37 °C for 2 min under stirring with 1 mM CaCl2 (final concentration). Aggregation was triggered with agonists after preincubation of platelets with different concentrations of PLA2 (20, 40, 80 and 160 µg/mL) at 37 °C for 30 min. Agonists ADP (20 µM) and collagen (10 µg/mL) (Helena Laboratories, Beaumont, TX, USA) were used as positive controls of reaction and their concentrations were determined according to the manufacturer’s instructions.
3.7. Edema-Inducing Activity
Crude venom (10 µg/50 µL saline), BpPLA2-TXI (10 µg/50 µL saline) or saline were injected into the subplantar region of male Swiss mice (18–22 g, n = 5). After 0.5, 1, 2, 3, 6 and 24 h, paw edema was measured with the aid of a low-pressure spring caliper (Mitutoyo, Tokyo, Japan). Zero time values were then subtracted and the differences reported as mean ± S.D.
3.8. Myotoxic Activity
Four groups of male Swiss mice (18–25 g, n = 4) were injected i.m. into the right gastrocnemius muscle with saline, crude venom (20 µg/50 µL Saline), BpPLA2-TXI (20 µg/50 µL Saline) or BnSP-7 (20 µg/50 µL), a Lys49 PLA2 previously isolated from B. pauloensis snake venom according to Soares et al. . The control was 0.9% NaCl. After 3 h, the animals were anesthetized (ketamine® 10% (0.05 mL/kg) + xylazine® 2% (0.025 mL/kg)) and the blood was collected by cardiac puncture in heparin-coated tubes and centrifuged (2500 × g for 10 min at 4 °C) for separation of the serum. The amount of creatine kinase (CK) was then determined with 50 µL of serum, which was incubated for 3 min at 37 °C with 1.0 mL of the reagent according to the CK-Nac protocol (Gold Analisa Diagnóstica LTDA, Belo Horizonte, Brazil). Activity was expressed in U/L, with one unit resulting from the phosphorylation of 1 µmole of creatine/min at 25 °C.
3.9. Cell Culture
MEF (Mouse Embryonic Fibroblast), Sarcoma 180 (TIB-66), TG-180 (CCRF S 180 II) and human ovarian carcinoma (OVCAR-3) cancer cell lines were maintained on RPMI 1640 medium supplemented with 2 mM l-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, 10% fetal bovine serum and 10 μg/mL gentamicin. All cell culture reagents were purchased from Gibco (São Paulo, Brazil). All cell lines were maintained at 37 °C in 5% CO2 and 95% air containing more than 95% humidity.
3.10. Cytotoxicity Activity
Tumor cells were cultivated in appropriate flasks and continuously maintained at exponential growth. The tumor cells then were transferred to tubes and washed three times with RPMI medium at 500 × g for 10 min at room temperature. Cells were suspended in 5 mL of RPMI complete medium and dispersed in 96-well plates at a density of 1 × 105 cells/well. After 24 h, the media were removed and fresh media, with or without different concentrations of BpPLA2-TXI (200–0.01 mg/mL), were added into the wells and incubated for 24 h. Cytotoxic activity of PLA2 was assayed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining and the MTT reduction was quantified at 540 nm. The cytotoxicity rate was calculated as follows: Cytotoxicity (%) = (1 − absorbance of the treated wells)/(absorbance of the control wells) × 100%.
3.11. Statistical Analysis
The results were presented as mean ± standard deviation (S.D.). Statistical significance of results was evaluated using the Student’s t-test. A value of p > 0.05 was considered significant.
3.12. Determination of Complete cDNA Sequence
The venom gland from B. pauloensis adult snake was dissected 3 days after venom extraction, when transcription was most stimulated . The pair of venom glands was homogenized under liquid nitrogen and the total RNA was extracted using the Trizol (Gibco) method. tRNA was dissolved in sterile milli-Q water (Billerica, MA, USA) and submitted to reverse-transcription polymerase chain reaction (RT-PCR). Two microliters of this sample was used to amplify the specific PLA2 cDNA, by using the specific primer PLA2-forward (5'-GAT CAT GAA AAT TGC GGG GA-3'), which was designed according to the N-terminal sequence, as determined for BpPLA2-TXI, and the universal M13 reverse primer (5'-CAG GAA ACA GCT ATG AC-3' GE Healthcare, Uppsala, Sweden) by PCR. After the amplification of the obtained cDNA, the PCR products were analyzed in regard to the amplified size by means of gel electrophoresis on 1% agarose. The gel was stained with ethidium bromide (0.5 mg/mL) and revealed under UV light. The PCR bands were purified by using the Concert Rapid PCR Purification System (Gibco BRL, São Paulo, Brazil) kit, according to the manufacturer’s specifications. The amplified fragment was cloned into a p-GEM-T Easy Vector System (Promega®, São Paulo, Brazil). Bacteria were selected on a medium containing ampicillin and visualized after adding isopropylthio-β-galactoside (IPTG) and X-Gal in the culture medium. After selection, the colonies of recombinant bacteria were assayed by PCR and gel electrophoresis for cloning confirmation. The PCR products were purified and submitted to sequencing, using the kit DYEnamic ET Terminator Cycle Sequencing Kit (GE Healthcare Uppsala, Sweden) in a MEGA-BACE 1000 automated DNA sequencer (GE Healthcare, Uppsala, Sweden). The Base Caller Cimarron 3.12 software (Amersham Biosci., Sunnyvale, CA, USA) was used in order to analyze the electropherograms and generate the sequences. The cDNA sequences corresponding to acidic PLA2s were identified and the full-length sequence was obtained.
3.13. Phylogenetic Analysis
The predicted sequences of the acidic PLA2 (BpPLA2-TXI) and other snake venom PLA2s were aligned by ClustalW program (UCD, Dublin, Ireland; http://www.ebi.ac.uk/Tools/clustalw2/index.html) while employing Human Synovial PLA2 as the out-group. Datasets were analyzed using Bayesian inference implemented on MrBayes, version 3.2.1  using lset rate s = invgamma with prset aamodelpr = mixed, which enables the program to optimize between nine different amino acid substitution matrices. The analysis was performed by running a minimum of 1.5 × 107 generations in four chains, and saving every 100th tree. The log-likelihood score of each saved tree was plotted against the number of generations to establish the point at which the log likelihood scores reached their asymptote, and the posterior probabilities for clades established by constructing a majority-rule consensus tree for all trees generated after completion of the burn-in phase.
BpPLA2-TXI isolated from B. pauloensis snake venom is an acidic D49 PLA2 that shows high catalytic activity, platelet aggregation inhibition, edematogenic and myotoxic activities. This enzyme shares a high degree of sequence identity and a great similarity with other acidic PLA2s, especially with D49 and E6, thus forming a group distinct from the basic PLA2s.
The authors gratefully acknowledge the financial support by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), CAPES, Universidade Federal de Uberlândia (UFU), National Institute of Science and Technology (INCT) in Nano-Biopharmaceutical, Brazil and the technical support of Fundação Ezequiel Dias (Belo Horizonte, Minas Gerais, Brazil).
Conflicts of Interest
The authors declare no conflict of interest.
- Valle, A.L.; Brites, V.L.C. Nomes populares e aspectos ecológicos de Bothrops pauloensis (Amaral, 1925) em áreas antropizadas do Triângulo e Alto Paranaíba, Minas Gerais. Rev. Bras. Zoociências 2008, 20, 155–161.
- Rodrigues, R.S.; Boldrini-França, J.; Fonseca, F.P.P.; de la Torre, P.; Henrique-Silva, F.; Sanz, L.; Calvete, J.J.; Rodrigues, V.M. Combined snake venomics and venom gland transcriptomic analysis of Bothropoides pauloensis. J. Proteom. 2012, 75, 2707–2720, doi:10.1016/j.jprot.2012.03.028.
- Burke, J.E.; Dennis, E.A. Phospholipase A2 Biochemistry. Cardiovasc. Drugs Ther. 2009, 23, 1–22, doi:10.1007/s10557-008-6151-6.
- Kudo, I.; Murakami, M. Phospholipase A2 enzymes. Prostag. Other Lipid Mediat. 2002, 69, 3–58, doi:10.1016/S0090-6980(02)00020-5.
- Schaloske, R.H.; Dennis, E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761, 1246–1259, doi:10.1016/j.bbalip.2006.07.011.
- Burke, J.E.; Dennis, E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipids Res. 2009, 50, 237–242, doi:10.1194/jlr.R800033-JLR200.
- Arni, R.K.; Ward, R.I. Phospolipase A2—A structural review. Toxicon 1996, 34, 827–841, doi:10.1016/0041-0101(96)00036-0.
- Teixeira, S.S.; Silveira, L.B.; Silva, F.M.N.; Marchi-Salvador, D.P.; Silva, F.P., Jr.; Izidoro, L.F.M.; Fuly, A.L.; Juliano, M.A.; Santos, C.R.; Murakami, M.T.; et al. Molecular characterization of an acidic phospholipase A2 from Bothrops pirajai snake venom: Synthetic-peptide identifies its anti-platelet region. Arch. Toxicol. 2011, 85, 1219–1233, doi:10.1007/s00204-011-0665-6.
- Silveira, L.B.; Marchi-Salvador, D.P.; Santos-Filho, N.A.; Silva, F.P., Jr.; Marcussi, S.; Fuly, A.L.; Nomizo, A.; Silva, S.L.; Stábeli, R.G.; Arantes, E.C.; et al. Isolation and expression of a hypotensive and anti-platelet acidic phospholipase A2 from Bothrops moojeni snake venom. J. Pharm. Biomed. Anal. 2013, 73, 35–43, doi:10.1016/j.jpba.2012.04.008.
- Rodrigues, V.M.; Marcussi, S.; Cambraia, R.S.; de Araújo, A.L.; Malta-Neto, N.R.; Hamaguchi, A.; Ferro, E.A.V.; Homsi-Brandeburgo, M.I.; Giglio, J.R.; Soares, A.M. Bactericidal and neurotoxic activities of two myotoxic phospholipases A2 from Bothrops neuwiedi pauloensis snake venom. Toxicon 2004, 44, 305–314, doi:10.1016/j.toxicon.2004.06.008.
- Soares, A.M.; Guerra-Sá, R.; Borja-Oliveira, C.R.; Rodrigues, V.M.; Rodrigues-Simioni, L.; Rodrigues, V. Structural and functional characterization of BnSP-7, a Lys49 myotoxic PLA2 homologue from Bothrops neuwiedi pauloensis venom. Arch. Biochem. Biophys. 2000, 37, 201–209.
- Rodrigues, R.S.; Izidoro, L.F.M.; Teixeira, S.S.; Silveira, L.B.; Hamaguchi, A.; Homsi-Brandeburgo, M.I.; Selistre-de-Araujo, H.S.; Giglio, J.R.; Fuly, A.L.; Soares, A.M.; et al. Isolation and functional characterization of a new myotoxic acidic phospholipase A2 from Bothrops pauloensis snake venom. Toxicon 2007, 50, 153–165, doi:10.1016/j.toxicon.2007.03.005.
- Denegri, M.E.G.; Acosta, O.C.; Huancahuire-Veja, S.; Martins-de-Souza, C.; Marangoni, S.; Marunak, S.L.; Teibler, G.P.; Leiva, L.C.; Ponce-Soto, L.A. Isolation and functional characterization of a new acidic PLA2 Ba SpII RP4 of the Bothrops alternatus snake venom from Argentina. Toxicon 2010, 56, 64–74, doi:10.1016/j.toxicon.2010.02.031.
- Santos-Filho, N.A.; Silveira, L.B.; Oliveira, C.Z.; Bernardes, C.P.; Menaldo, D.L.; Fuly, A.L.; Arantes, E.C.; Sampaio, S.V.; Mamede, C.C.N.; Beletti, M.E.; et al. A new acidic myotoxic, anti-platelet and prostaglandin I2 inductor phospholipase A2 isolated from Bothrops moojeni snake venom. Toxicon 2008, 52, 908–917, doi:10.1016/j.toxicon.2008.08.020.
- Magro, A.J.; Soares, A.M.; Giglio, J.R.; Fontes, M.R.M. Crystal structures of BnSP-7 and BnSP-6, two Lys49-phospholipases A2: Quaternary structure and inhibition mechanism insights. Biochem. Biophys. Res. Comun. 2003, 311, 713–720, doi:10.1016/j.bbrc.2003.10.047.
- Soares, A.M.; Fontes, M.R.M.; Giglio, J.R. Phospholipase A2 myotoxins from Bothrops snake venoms: Structure-function relationship. Curr. Org. Chem. 2004, 8, 1–14, doi:10.2174/1385272043486124.
- Marchi-Salvador, D.P.; Fernandes, C.A.H.; Silveira, L.B.; Soares, A.M.; Fontes, M.R.M. Crystal structure of a phospholipase A2 homologue complexed with p-bromophenacyl bromide reveals important structural changes associated with the inhibition of myotoxic activity. Biochim. Biophys. Acta 2009, 1794, 1583–1590, doi:10.1016/j.bbapap.2009.07.005.
- Dennis, E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. TiBS 1997, 22, 1–2.
- Fernández, J.; Gutiérrez, J.M.; Angulo, Y.; Sanz, L.; Juárez, P.; Calvete, J.J.; Lomonte, B. Isolation of an acidic phospholipase A2 from the venom of the snake Bothrops asper of Costa Rica: Biochemical and toxicological characterization. Biochimie 2010, 92, 273–283, doi:10.1016/j.biochi.2009.12.006.
- Andrião-Escarso, S.H.; Soares, A.M.; Fontes, R.M.; Fuly, A.L.; Corrêa, F.M.A.; Rosa, J.C.; Greene, L.J.; Giglio, J.R. Structural and functional characterization of an acidic platelet aggregation inhibitor and hypotensive phospholipase A2 from Bothrops jararacussu snake venom. Biochem. Pharmacol. 2002, 64, 723–732, doi:10.1016/S0006-2952(02)01210-8.
- Fuly, A.L.; Calil-Elias, S.; Martinez, A.M.; Melo, P.A.; Guimarães, J.A. Miotoxicity induced by an acidic Asp-49 phospholipase A2 isolated from Lachesis muta (Bushmaster) snake venom. Comparison with lysophosphatidylcholine. Int. J. Biochem. Cell Biol. 2003, 35, 1470–1481, doi:10.1016/S1357-2725(03)00129-8.
- Gutiérrez, J.M.; Ownby, C.L. Skeletal muscle degeneration induced by venom phospholipases A2: Insights into the mechanisms of local and systemic myotoxicity. Toxicon 2003, 42, 915–931, doi:10.1016/j.toxicon.2003.11.005.
- Stábeli, R.G.; Amui, S.F.; Sant’ana, C.D.; Pires, M.G.; Nomizo, A.; Monteiro, M.C.; Romão, P.R.T.; Guerra-Sá, R.; Vieira, C.A.; Giglio, J.R.; et al. Bothrops moojeni myotoxin-II, a Lys-49-phospholipase A2 homologue: An example of function versatility of snake venom proteins. Compar. Biochem. Physiol. 2006, 142, 371–381.
- Costa, T.R.; Menaldo, D.L.; Oliveira, C.Z.; Santos-Filho, N.A.; Teixeira, S.S.; Nomizo, A.; Fuly, A.L.; Monteiro, M.C.; Souza, B.M.; Palma, M.S.; et al. Myotoxic phospholipase A2 isolated from Bothrops brazili snake venom and synthetic peptides derived from their C-terminal region: Cytotoxic effect on microorganism and tumor cells. Peptides 2008, 29, 1645–1656, doi:10.1016/j.peptides.2008.05.021.
- Modesto, J.C.A.; Spencer, P.J.; Fritzen, M.; Valença, R.C.; Oliva, M.L.; da Silva, M.B.; Chudzinski-Tavassi, A.M.; Guarnieri, M.C. BE-I-PLA2, a novel acidic phospholipase A2 from Bothrops erythromelas venom: Isolation, cloning and characterization as potent anti-platelet and inductor of prostaglandin I2 release by endothelial cells. Biochem. Pharmacol. 2006, 72, 377–384, doi:10.1016/j.bcp.2006.04.032.
- Nakashima, K.; Nobuhisa, I.; Deshimaru, M.; Nakai, M.; Ogawa, T.; Shimohigashi, Y.; Fukumaki, Y.; Hattori, M.; Sakaki, Y.; Hattori, S.; et al. Accelerated evolution in the protein-coding regions is universal in crotalinae snake venom gland phospholipase A2 isozyme genes. Proc. Natl. Acad. Sci. USA 1995, 92, 5605–5609, doi:10.1073/pnas.92.12.5605.
- Chen, Y.H.; Wang, Y.M.; Hseu, M.J.; Hseu, M.J.; Tsai, I.H. Molecular evolution and structure-activity relationships of crotoxin-B like asparagin 6 phospholipase A2 in pit viper venom. Biochem. J. 2004, 381, 61–73.
- Chijiwa, T.; Tokunaga, E.; Ikeda, R.; Terada, K.; Ogawa, T.; Oda-Ueda, N.; Hattori, S.; Nozaki, M.; Ohno, M. Discovery of novel (Arg49) phospholipase A2 isoenzymes from ProtoBothrops elegans venom and regional evolution of Crotalinae snake venom phospholipase A2 isoenzymes in the southwestern islands of Japan and Taiwan. Toxicon 2006, 48, 672–682, doi:10.1016/j.toxicon.2006.06.021.
- Gibbs, H.L.; Rossiter, W. Rapid evolution by positive selection and gene gain and loss: PLA2 venom genes in closely related Sistrurus rattlesnakes with divergent diets. J. Mol. Evol. 2008, 66, 151–166, doi:10.1007/s00239-008-9067-7.
- Tsai, I.H.; Chen, Y.H.; Wang, Y.M.; Tu, A.T. Geographic variations, cloning and functional analyses of the venom acidic phospholipases A2 of Crotalus viridis viridis. Arch. Biochem. Biophys. 2003, 411, 289–296, doi:10.1016/S0003-9861(02)00747-6.
- Naves, D.L.N.; Gomes, M.S.R.; Ferreira, F.B.; Rodrigues, R.S.; Achê, D.C.; Rochardson, M.; Borges, M.H.; Rodrigues, V.M. Biochemical and enzymatic characterization of BpMP-I, a fibrinogenolytic metalloproteinase isolated from Bothropoides. pauloensis snake venom. Comp. Biochem. Physiol. 2012, 161, 102–109.
- Ferreira, F.B. Federal University of Uberlândia, Uberlândia, MG, Brazil, 2011. Unpublished work.
- Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680–685, doi:10.1038/227680a0.
- De-Haas, G.H.; Postema, N.M.; Nieuwenhuiaen, W.; van Deenen, L.L.M. Purification and properties of phospholipase A2 from porcine pancreas. Biochim. Biophys. Acta 1968, 159, 103–117, doi:10.1016/0005-2744(68)90248-9.
- Gutierrez, J.M.; Avila, C.; Rojas, E.; Cerdas, L. Alternative in vitro method for testing the potency of the polyvalent antivenom produced in Costa Rica. Toxicon 1988, 26, 411–413, doi:10.1016/0041-0101(88)90010-4.
- Paine, M.J.I.; Desmond, H.P.; Theakston, R.D.G.; Crampton, J.M. Gene expression in Echis carinatus (carpet viper) venom glands following milking. Toxicon 1992, 30, 379–386, doi:10.1016/0041-0101(92)90534-C.
- Ronquist, F.; Teslenko, M.; van der Mark, P.; Ayres, D.; Darling, A.; Hohna, S.; Larget, B.; Liu, L.; Suchard, M.A.; Huelsenbeck, J.P. MrBayers 3.2: Efficient Bayesian phylogenetic inference and model choice across a large model space. Syst. Biol. 2012, 3, 539–542.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).